Immediate feedback of HbA1c levels improves glycemic control in type I and insulin-treated type 2 diabetic patients
Immediate feedback of HbA1c levels improves glycemic control in type I and insulin-treated type 2 diabetic patients
复制标题
DOI：
10.2337/diacare.22.11.1785
复制
发表时间：
1999-11-01
期刊：
影响因子：
16.2
通讯作者：
Nathan, DM
中科院分区：
文献类型：
--
作者：
Cagliero, E;Levina, EV;Nathan, DM
目的：在门诊就诊时，使用台式分析仪可以获得准确可靠的HbA（1c）结果。我们测试的假设，即立即可用的HbA（1C）的结果，可以改善血糖控制通过改变医生或患者的行为或both.RESEARCH设计和方法-一个随机对照试验进行了201型1和胰岛素治疗的2型糖尿病患者参加学术糖尿病中心。在12个月的随访期内，对HbA（1c）水平、胰岛素治疗的变化和医疗资源的使用进行了评估。结果-即刻测定组的HbA（1c）水平在6个月和12个月时显著下降（分别为-0.57 +/- 1.44和-0.40 +/-1.65%; P < 0.01），但对照组无变化（分别为-0.11 +/- 0.79和-0.19 +/-1.16%; NS）。1型和2型糖尿病患者的变化相似。有低血糖事件的发生率或使用的卫生保健resources.CONCLUSIONS -在设置一个对照随机试验，即时反馈的HbA（1C）结果在病人遇到的时间导致在6个月的随访血糖控制显着改善，并持续了12个月的研究。该检测方法的引入受到了患者和医生的积极欢迎。
OBJECTIVE - Accurate and reliable HbA(1c) results can be obtained at the time of the office visit by using benchtop analyzers. We tested the hypothesis that immediately available HbA(1c) result; could improve glycemic control by changing physician or patient behavior or both.RESEARCH DESIGN AND METHODS- A randomized controlled trial was conducted in 201 type 1 and insulin-treated type 2 diabetic patients attending an academic diabetes center. HbA(1c) levels, changes in insulin therapy, and use of health care resources were assessed during a 12-month follow-up period.RESULTS - HbA(1c) levels decreased significantly at 6 and 12 months in the immediate assay group (-0,57 +/- 1.44 and -0.40 +/- 1.65%, respectively; P < 0.01) but did not change in the control group (-0.11 +/- 0.79 and -0.19 +/- 1.16%, respectively; NS). The changes were similar for both type 1 and type 2 diabetic patients. There were no differences in the rates of hypoglycemic events or use of health care resources.CONCLUSIONS - In the setting of a controlled randomized trial, the immediate feedback of HbA(1c) results at the time of patient encounters resulted in a significant improvement of glycemic control at 6-month follow-up and persisted for the 12-month study . The introduction of this assay was positively received by both patients and physicians.